The estimated Net Worth of Kevin D. Bunker is at least $24.3 Milión dollars as of 4 October 2023. Dr Bunker owns over 6,068 units of Zentalis Pharmaceuticals, Llc stock worth over $2,792,039 and over the last 5 years he sold ZNTL stock worth over $20,768,212. In addition, he makes $699,495 as Chief Operating Officer at Zentalis Pharmaceuticals, Llc.
Dr has made over 36 trades of the Zentalis Pharmaceuticals, Llc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,068 units of ZNTL stock worth $118,326 on 4 October 2023.
The largest trade he's ever made was selling 80,000 units of Zentalis Pharmaceuticals, Llc stock on 26 May 2023 worth over $2,401,600. On average, Dr trades about 10,887 units every 31 days since 2020. As of 4 October 2023 he still owns at least 859,089 units of Zentalis Pharmaceuticals, Llc stock.
You can see the complete history of Dr Bunker stock trades at the bottom of the page.
Dr. Kevin D. Bunker Ph.D. is the Chief Operating Officer at Zentalis Pharmaceuticals, Llc.
As the Chief Operating Officer of Zentalis Pharmaceuticals, Llc, the total compensation of Dr D at Zentalis Pharmaceuticals, Llc is $699,495. There are 1 executives at Zentalis Pharmaceuticals, Llc getting paid more, with Dr. Anthony Y. Sun M.D. having the highest compensation of $957,285.
Dr D is 48, he's been the Chief Operating Officer of Zentalis Pharmaceuticals, Llc since . There are 3 older and 1 younger executives at Zentalis Pharmaceuticals, Llc. The oldest executive at Zentalis Pharmaceuticals, Llc is Dr. Dimitris Voliotis M.D., 57, who is the Sr. VP of Clinical Devel..
Kevin's mailing address filed with the SEC is C/O ZENTALIS PHARMACEUTICALS, INC., 1359 BROADWAY SUITE 801, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Zentalis Pharmaceuticals, Llc have traded over $106,453,887 worth of Zentalis Pharmaceuticals, Llc stock and bought 5,536,611 units worth $121,990,782 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management Company,... a Anthony Y Sun. On average, Zentalis Pharmaceuticals, Llc executives and independent directors trade stock every 11 days with the average trade being worth of $188,516. The most recent stock trade was executed by Cam Gallagher on 31 May 2024, trading 9,597 units of ZNTL stock currently worth $114,972.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Zentalis Pharmaceuticals, Llc executives and other stock owners filed with the SEC include: